Promoting Early Identification of Systemic Anti-Cancer Therapies Side Effects: Two Approaches

In response to concerns that patients often delay reporting serious Systemic Anti-Cancer Therapy (SACT) side effects, the National Chemotherapy Board (NCB) has developed guidance to improve side effect reporting. Two complementary approaches are suggested: Firstly empowerment, which focuses on equipping patients to take responsibility for identifying and reporting important side effects. This may be mediated through technology such as use of mobile phones or the internet.
 
Secondly, proactive monitoring, which includes clinician interventions (e.g. telephone support or home visits). There is some evidence that patients find pro-active calls from nurses supportive and reassuring during SACT. Current evidence suggests that proactive monitoring results in earlier symptom management than patient self reports.
 
To read the guidance, please click here.
 

Latest News

By BOPA on 16th April 2024

Abstract Submission for #BOPA2024 is NOW OPEN

Abstract Submission for the 27th Annual BOPA Conference in 2024 is now OPEN   Delegates are invited to present results of their clinical and technical work as a poster with…

Read article
By BOPA Research Subcommittee on 15th April 2024

Survey: Service Evaluation on Carboplatin Variation in UK

We invite members to complete this service evaluation to understand national variations in carboplatin dosing for adult patients receiving SACTs. We are looking at whether we can standardise carboplatin protocols…

Read article
By BOPA on 11th April 2024

My Research Webinar – April 2024

Thursday 25th April 2024 1-2pm BST   Register for the Session HERE: https://www.bopa.org.uk/webinarsignupform/   We would like to invite you to join our  ‘My Research’ sessions. These sessions are delivered…

Read article
By BOPA Committee on 10th April 2024

Independent UK Pharmacy Professional Leadership Advisory Board launched to strengthen collaboration

BOPA is proud to be part of the UK PPL Board and represent all Pharmacy Professionals and Cancer Pharmacy Professionals across the UK. For more information see the letter on…

Read article